The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.

摘要: Antiangiogenic agents produce regression in few tumors clinical trials, but are effective preventing recurrences. To determine whether the vascular endothelial growth factor (VEGF) receptor is a molecular target to prevent metastatic disease, we utilized non-specific inhibitor of VEGF receptor, SU11248. This tyrosine kinase (RTK) prevented migration cells and markedly attenuated capillary-like tubule formation culture. Similarly, this agent blood vessel tumor window model. RTK inhibition produced minimal effects on established vessels model little effect flow studied by power Doppler analysis. these attenuate development metastases, Lewis lung carcinoma were resected from dorsal skin metastases quantified with without treatment The following resection hind limb tumor. In contrast, did not induce primaries slowed progression growth. These findings suggest that greatest role for antagonists may be new vessels, during after conventional therapy given existing neoplastic disease.